Campo DC | Valor | Idioma |
dc.contributor.author | Solon, Lílian Grace da Silva | - |
dc.contributor.author | Guerra, Gerlane Bernardo Coelho | - |
dc.contributor.author | Araújo, Aurigena Antunes de | - |
dc.contributor.author | Barichello, José Mário | - |
dc.contributor.author | Pérez Urizar, José | - |
dc.contributor.author | Soares, Luiz Alberto Lira | - |
dc.creator | Solon, Lílian Grace da Silva | - |
dc.creator | Guerra, Gerlane Bernardo Coelho | - |
dc.creator | Araújo, Aurigena Antunes de | - |
dc.creator | Barichello, José Mário | - |
dc.creator | Pérez Urizar, José | - |
dc.creator | Soares, Luiz Alberto Lira | - |
dc.date.accessioned | 2013-09-12T17:06:42Z | - |
dc.date.available | 2013-09-12T17:06:42Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 2176-9451 | - |
dc.identifier.uri | http://www.repositorio.ufba.br/ri/handle/ri/12925 | - |
dc.description | p.48-54 | pt_BR |
dc.description.abstract | The purpose of this study was to determine naproxen concentrations in rat plasma samples by HPLC and to compare the bioavailability of a generic and two compounded naproxen sodium suspensions (test 1 and test 2). Analysis was run at a fl ow rate of 1.2 mL.min-1 with a mobile phase of acetonitrile: NaH2PO4 0.01 M pH 4.00 (50:50, v/v) at 280 nm, using a C18 column (150 mm x 4.6 mm, 5 μm). The calibration curve was linear (R2 = 0.9987) over the range of 0.25 - 200 μg.mL-1. The precision for inter and intra-day analysis ranged from 2.46% to 12.39%. Cmax, Tmax and AUCt were 191.25 ± 11.17 μg.mL-1, 1.00 ± 0.106 h and 2438.16 ± 291.34 μg.h.mL-1 for the reference drug, 188.22 ± 24.78 μg.mL-1, 1.06 ± 0.092 h and 1755.02 ± 228.90 μg.h.mL-1 for test 1, and 160.50 ± 10.58 μg.mL-1, 0.66 ± 0.102 h and 1955.28 ± 142.80 μg.h.mL-1 for test 2. No signifi cant differences were found based on analysis of variance, with mean values and 90% CI of test2/reference ratio (Cmax 83.92% and AUCt 80.19%). For test1/reference ratio, the result was Cmax 98.41% and AUCt 71.98%. Based on these results, it can be concluded that the validated method was successfully applied to this study; the test 1 formulation failed to demonstrate a bioequivalence to the reference drug; however, the test 2 and reference naproxen sodium suspension were bioequivalent in terms of the rate and extent of absorption under these conditions. | pt_BR |
dc.language.iso | en | pt_BR |
dc.source | http://dx.doi.org/10.4172/1948-593X.1000021 | pt_BR |
dc.subject | Bioavailability studies | pt_BR |
dc.subject | Validation | pt_BR |
dc.subject | HPLC | pt_BR |
dc.subject | Pharmacokinetics | pt_BR |
dc.subject | Compounded naproxen sodium suspension | pt_BR |
dc.title | Comparative bioavailability of a generic and two compounded naproxen sodium suspensions administered to rats | pt_BR |
dc.title.alternative | Dental Press Journal of Orthodontics | pt_BR |
dc.type | Artigo de Periódico | pt_BR |
dc.identifier.number | v. 2, n. 2 | pt_BR |
Aparece nas coleções: | Artigo Publicado em Periódico (FAR)
|